Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

• C. Grávalos ^[1] ; O. Sanmartín ^[2] ; A. Gúrpide ^[3] ; A. España ^[3] ; M. Majem ^[4] ; H. J. Suh Oh ^[5] ; I. Aragón ^[9] ; S. Segura ^[6] ; C. Beato ^[7] ; R. Botella ^[8]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  3. [3] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  4. [4] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  5. [5] Complexo Hospitalario Universitario de Pontevedra

     Complexo Hospitalario Universitario de Pontevedra

     Pontevedra, España

     
  6. [6] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  7. [7] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  8. [8] Instituto de Investigación Sanitaria La Fe

     Instituto de Investigación Sanitaria La Fe

     Valencia, España

     
  9. [9] Complejo Hospitalario Universitario de Huelva

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 5 (May), 2019, págs. 556-571
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.